{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:55:55Z","timestamp":1783605355102,"version":"3.55.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,28]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>BV plus DTIC is an active and well-tolerated combination for patients aged \u226560 years with HL. Although highly active at the doses evaluated, BV plus bendamustine has unacceptable toxicity in patients aged \u226560 years with HL.<\/jats:p>","DOI":"10.1182\/blood-2017-06-787200","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T20:55:22Z","timestamp":1508187322000},"page":"2829-2837","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":82,"title":["Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL"],"prefix":"10.1182","volume":"130","author":[{"given":"Jonathan W.","family":"Friedberg","sequence":"first","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo E.","family":"Bordoni","sequence":"additional","affiliation":[{"name":"Georgia Cancer Specialists, Marietta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian J. M.","family":"Cline","sequence":"additional","affiliation":[{"name":"Texas Oncology-Round Rock Seton Williamson, Round Rock, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Patel Donnelly","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists, Fairfax, VA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Flynn","sequence":"additional","affiliation":[{"name":"Minnesota Oncology, Woodbury, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg","family":"Olsen","sequence":"additional","affiliation":[{"name":"Providence Saint Joseph Medical Center, Burbank, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"City of Hope Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Fong","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc., Bothell, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Wang","sequence":"additional","affiliation":[{"name":"Seattle Genetics, Inc., Bothell, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Yasenchak","sequence":"additional","affiliation":[{"name":"Willamette Valley Cancer Institute and Research Center\/US Oncology Research, Eugene, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"17","key":"2019111907481517200_B1","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup trial of response-adapted therapy for Stage III to IV Hodgkin lymphoma using early interim Fluorodeoxyglucose-Positron Emission Tomography imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111907481517200_B2","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111907481517200_B3","author":"Howlader","year":"2014"},{"issue":"1","key":"2019111907481517200_B4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111907481517200_B5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","article-title":"How can outcomes be improved for older patients with Hodgkin lymphoma?","volume":"31","author":"Evens","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111907481517200_B6","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111907481517200_B7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3109\/10428194.2013.876496","article-title":"Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy","volume":"55","author":"Gopal","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"2019111907481517200_B8","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2019111907481517200_B9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9976","key":"2019111907481517200_B10","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2019111907481517200_B11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111907481517200_B12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111907481517200_B13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/089198879500800408","article-title":"Reliability of the blessed telephone information-memory-concentration test","volume":"8","author":"Kawas","year":"1995","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"9","key":"2019111907481517200_B14","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"issue":"25","key":"2019111907481517200_B15","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111907481517200_B16","first-page":"86","article-title":"Physical functioning measures","author":"Stewart","year":"1992"},{"issue":"4","key":"2019111907481517200_B17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/geronj\/36.4.428","article-title":"The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire","volume":"36","author":"Fillenbaum","year":"1981","journal-title":"J Gerontol"},{"issue":"suppl 1","key":"2019111907481517200_B18","first-page":"S85","article-title":"Pharmacokinetics of brentuximab vedotin in hodgkin lymphoma patients aged 60 and above","volume":"97","author":"Yang","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"s5","key":"2019111907481517200_B19","first-page":"45","article-title":"Brentuximab vedotin plus bendamustine as a salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma","volume":"101","author":"LaCasce","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2019111907481517200_B20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111907481517200_B21","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","article-title":"Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma","volume":"118","author":"B\u00f6ll","year":"2011","journal-title":"Blood"},{"issue":"25","key":"2019111907481517200_B22","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.1182\/blood-2011-12-396556","article-title":"Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study","volume":"119","author":"Proctor","year":"2012","journal-title":"Blood"},{"issue":"33","key":"2019111907481517200_B23","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2016.67.5926","article-title":"Comprehensive geriatric assessment-guided therapy does improve outcomes of older patients with advanced lung cancer","volume":"34","author":"Gajra","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111907481517200_B24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jgo.2015.10.183","article-title":"Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy","volume":"6","author":"Park","year":"2015","journal-title":"J Geriatr Oncol"},{"issue":"4","key":"2019111907481517200_B25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3109\/10428194.2014.935364","article-title":"Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma","volume":"56","author":"Aaldriks","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2019111907481517200_B26","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111907481517200_B27","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"issue":"35","key":"2019111907481517200_B28","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2013.49.8246","article-title":"Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111907481517200_B29","author":"Klimm","year":"2007"},{"key":"2019111907481517200_B30","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure [published online 27 June 2016]","author":"Armand","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111907481517200_B31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111907481517200_B32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"23","key":"2019111907481517200_B33","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111907481517200_B34","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1105.1105","article-title":"Preliminary results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma [abstract]","volume":"128","author":"Herrera","year":"2016","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/26\/2829\/1403610\/blood787200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/26\/2829\/1403610\/blood787200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:48:38Z","timestamp":1574149718000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/26\/2829\/36593\/Frontline-brentuximab-vedotin-in-combination-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":34,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,12,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-06-787200","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,28]]}}}